Enp.Ax
ENP.AX is a healthcare diagnostics company that develops and commercializes diagnostic tests and related technologies, primarily generating revenue through product sales and research collaborations.
Business. ENP.AX is a healthcare diagnostics company that develops and commercializes diagnostic tests and related technologies, primarily generating revenue through product sales and research collaborations.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
ENP.AX is a healthcare diagnostics company that develops and commercializes diagnostic tests and related technologies, primarily generating revenue through product sales and research collaborations.
ENP.AX maintains a strong liquidity position with a current ratio of 9.08, indicating that its current assets significantly exceed its current liabilities. The company holds $3,026,250 in cash and equivalents, which is a substantial portion of its total assets of $6,663,080. However, the company reported negative operating cash flow of $7,770,000 and free cash flow of $5,411,480, reflecting ongoing operational challenges.
Profitability metrics show significant underperformance relative to industry norms. The company reported a return on equity of -0.8941 and a return on assets of -0.8003, both of which are negative and suggest that the company is not generating returns for its shareholders or effectively utilizing its assets. These figures are well below the typical performance of firms in the biotechnology and medical research industry.
The company's revenue is concentrated in a single business segment focused on healthcare diagnostics, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare diagnostics sector, which is subject to regulatory and technological changes.
Growth trajectory appears to be constrained by the company's current financial performance. The company reported a net loss of $5,332,420 and an operating loss of $5,281,410, indicating that it is not currently generating positive earnings. There is no disclosed revenue growth or expansion into new markets, which limits its potential for future growth.
Risk factors include the company's negative cash flows and poor profitability, which could impact its ability to fund operations and invest in research and development. The company has no long-term debt, which reduces financial leverage risk, but the absence of dilution risk is offset by the lack of capital inflows to support growth initiatives.
Recent events include the latest financial filing, which shows continued operational losses and negative cash flows. There are no disclosed recent regulatory actions, product launches, or strategic partnerships that would indicate a shift in the company's trajectory. The absence of new developments suggests a stable but unimpressive operational environment.
- ENP.AX has a strong liquidity position with a current ratio of 9.08 and $3,026,250 in cash and equivalents.
- The company is unprofitable, with a return on equity of -0.8941 and a return on assets of -0.8003.
- Revenue is concentrated in a single segment with no geographic diversification, increasing market-specific risk.
- The company is not currently generating positive earnings, with a net loss of $5,332,420 and an operating loss of $5,281,410.
- There are no immediate liquidity or dilution risks, but the company's negative cash flows and poor profitability could impact its ability to fund operations and invest in growth.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- ENP.AX Market data — financials · 2026-05-27